Literature DB >> 1661764

Inhibition of angiotensin converting enzyme by ramipril in serum and tissue of man.

A Erman1, J Winkler, B Chen-Gal, M Rabinov, A Zelykovski, S Tadjer, J Shmueli, E Levi, A Akbary, J B Rosenfeld.   

Abstract

Studies in animal models have indicated that ramipril is a potent inhibitor of angiotensin converting enzyme (ACE) in serum and tissue. In our study, the normal range of ACE activity and the inhibitory effect of short-term oral administration of ramipril on ACE activity in human serum and tissue samples of renal cortex, heart and blood vessels were determined. ACE activity in the renal cortex (125.2 +/- 11.5 nmol/mg per min) was greater than 600 times that of the heart (0.20 +/- 0.01 nmol/mg per min), greater than 500 times that of the veins (0.23 +/- 0.09 nmol/mg per min) and greater than 150 times that of the arteries (0.80 +/- 0.23 nmol/mg per min). ACE activity in the renal cortex and arteries 2 h after last dosing was almost completely inhibited by ramipril whereas ACE activity in the veins and heart was inhibited to a lesser extent. Our results demonstrate in man, for the first time, an inhibition of tissue ACE following short-term oral treatment with an ACE inhibitor.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1661764     DOI: 10.1097/00004872-199111000-00012

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  4 in total

Review 1.  Inhibitors of the renin-angiotensin system in established cardiac failure.

Authors:  K Chatterjee
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

Review 2.  Overview of the relationship between ischemia and congestive heart failure.

Authors:  W J Remme
Journal:  Clin Cardiol       Date:  2000-07       Impact factor: 2.882

Review 3.  Ramipril. An updated review of its therapeutic use in essential hypertension and heart failure.

Authors:  J E Frampton; D H Peters
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546

4.  A randomized controlled trial of angiotensin-converting enzyme inhibition for skeletal muscle dysfunction in COPD.

Authors:  Dinesh Shrikrishna; Rebecca J Tanner; Jen Y Lee; Amanda Natanek; Amy Lewis; Patrick B Murphy; Nicholas Hart; John Moxham; Hugh E Montgomery; Paul R Kemp; Michael I Polkey; Nicholas S Hopkinson
Journal:  Chest       Date:  2014-10       Impact factor: 9.410

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.